North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Valeria C. Cohran, MD, emphasized the importance of close collaboration between intestinal rehab programs and general pediatricians to optimize care for children with intestinal failure.

Older age, longer remaining intestine, and presence of an ileocecal valve were linked with a greater likelihood of achieving sustained enteral autonomy in children with short bowel syndrome-associated intestinal failure.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

In this Contemporary Pediatrics video interview, Dale Lee, MD, highlights how pediatricians can be involved in celiac disease follow-up care.

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Long-term analysis of the PEDFIC studies presented at NASPGHAN 2025 demonstrated sustained reductions in bile acids and pruritus with odevixibat in FIC1 deficiency.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

At NASPGHAN 2025, investigators presented 52-week safety data from an ongoing phase 3 trial of linaclotide, the first approved treatment for patients aged 7 and older with IBS-C.

A multicenter study from NASPGHAN 2025 highlights geographic and immune-driven variations in pediatric H. pylori infection across the Americas.